Exagen (XGN) Q2 2026 earnings review
Record Revenue Breakout Puts Profitability in Sight
Exagen delivered a standout Q2, reporting record revenue of $19.9 million (up 16% YoY) and definitively breaking out of its recent $17 million quarterly plateau. The growth was driven by a robust 11% increase in AVISE CTD test volume and continued expansion in average selling prices (ASP). Most impressively, the top-line beat translated directly to the bottom line: Adjusted EBITDA loss narrowed to just $0.1 million, a massive improvement from the $1.7 million loss a year ago, proving the company's operating leverage. Management confidently raised full-year 2026 revenue guidance to $72-$75 million.
🐂 Bull Case
Gross margin expanded to 61.3% (from 60.4% YoY), while operating expenses grew just 7% despite a 16% revenue surge. The near-breakeven Adjusted EBITDA proves the business model can scale profitably.
The strategy of simultaneously expanding the sales force to drive volume (+11%) and executing on revenue cycle management to increase ASP (+4%) is yielding record top-line results.
🐻 Bear Case
While Adjusted EBITDA is nearing breakeven, cash and cash equivalents still declined to $24.6 million from $32.2 million at the end of 2025. Positive cash generation is required soon to avoid dilutive financing.
The long-awaited Medicare LCD from MolDx remains in limbo, and previous quarters indicated higher initial denial rates for new biomarkers, suggesting ASP gains require intensive administrative effort.
⚖️ Verdict: 🟢
Bullish. The Q2 revenue breakout combined with the sudden compression of EBITDA losses demonstrates that management's strategic shift toward disciplined execution is finally paying off. The raised guidance confirms momentum is sustainable.
Key Themes
Sales Force Expansion Driving Volume Growth
AVISE CTD test volume grew 11% YoY in Q2, accelerating from the 10% pace set in Q1. This indicates that the 2025 expansion of the sales force to 45 territories is successfully maturing, driving deeper market penetration and outpacing the estimated 5% autoimmune testing market growth rate.
Revenue Cycle Management Securing ASP Gains
Trailing twelve-month (TTM) ASP for AVISE CTD reached $446, up $18 (4%) YoY. This marks uninterrupted sequential growth over the last several quarters, demonstrating that the company's aggressive appeals process and focus on prior-period collections are successfully extracting more value per test, moving closer to their long-term $600-$650 target.
Strengthening Clinical Utility Evidence
A new systematic review of over 3,100 patients across 14 medical centers validated that AVISE Lupus correctly identified approximately 25% of systemic lupus erythematosus (SLE) patients missed by conventional markers. This robust, real-world data arms the sales team with a powerful clinical narrative to convert holdout rheumatologists.
ASP Predictability and Payer Pushback
In Q1, the company disclosed that in-period ASP was heavily inflated by a massive $900k one-time collection of older claims. It is unclear how much of Q2's revenue outperformance was driven by similar lumpy, unpredictable prior-period collections versus structural reimbursement rate improvements from commercial payers.
Medicare LCD Timing Remains Uncertain
A Local Coverage Determination (LCD) from Medicare's MolDx program is the most critical macro catalyst for the company to secure permanent, predictable ASP increases. Despite management stating they are 'in the queue' during the Q1 call, there remains no clear timeline for this pivotal regulatory decision.
Other KPIs
Stable and incrementally improving. Gross margin expanded 90 basis points from 60.4% in 26Q2, driven by higher ASP and economies of scale on higher test volumes. This is approaching management's long-term target of the mid-60s.
Stable. Total operating expenses increased by only 7% YoY (from $13.0M in 25Q2), significantly trailing the 16% revenue growth. This expense discipline—holding SG&A and R&D relatively flat—was the primary catalyst for the near-elimination of the Adjusted EBITDA loss.
Declining. While Adjusted EBITDA was near breakeven, the company still reported a net loss of $3.2M for the quarter, and cash balances fell from $32.2M at the end of 2025. Given the non-cash expenses, closely monitoring operating cash flow will be vital in H2 2026.
Guidance
Accelerating. The guidance was raised from the previous $70-$73 million range. The new midpoint ($73.5M) implies a 10.4% YoY growth rate over FY25's $66.6M. However, since H1 2026 revenue grew 14% YoY, this guidance implies a deceleration in growth for the second half of the year, which may reflect management conservatism or anticipated seasonal headwinds.
Key Questions
ASP Quality and Predictability
Given the substantial prior-period claim collections that boosted Q1 revenue, how much of Q2's record top-line and ASP expansion was driven by structural, in-period payer improvements versus one-time catch-up collections?
Volume Growth Breakdown
With 11% volume growth this quarter, can you separate the growth coming from increased productivity in tenured territories versus the initial ramp of the newer sales reps hired late last year?
Pathway to Free Cash Flow
Adjusted EBITDA has reached near breakeven, yet cash balances have declined by roughly $7.6 million since year-end. What are the working capital dynamics driving this gap, and when exactly do you anticipate achieving sustained positive free cash flow?
H2 Guidance Conservatism
H1 revenue grew roughly 14% YoY, but the raised full-year guidance midpoint implies growth will decelerate to the single digits in the back half of the year. Are you anticipating specific seasonal headwinds, or is this simply prudent forecasting?